TBI Institutional Ownership

TrueBlue, Inc.

Latest close $10.20 as of Aug 7, 2026

TBI institutional ownership at a glance

Follow TrueBlue, Inc. institutional ownership through recent Schedule 13G and 13D filings. Compare reported shares, ownership percentages, filing dates, and changes in beneficial ownership over time.

Latest filing: Invesco filed Schedule 13G amendment on May 8, 2026, reporting 49.6K shares and 12.00% beneficial ownership.

Browse recent ownership filings How Schedule 13G works Why a 13G is not a trade report

How to read Schedule 13 ownership changes

Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.

Form 13F rows are quarter-end holding context only and do not establish an exact entry date.

For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.

Current ownership filings and reported ownership changes are available on free access. Investor and Pro add filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and alerts. The overall institutional consensus preview remains public. Compare plans.

Cross-institution intelligence

Institutional Research

This gauge summarizes recent agreement across tracked institutional activity.

Latest filing May 8, 2026

Public consensus preview Broad reduction 12/100 institutional research score

3 tracked institutions Latest filing May 8, 2026

2 reducing across 2 comparable institutions.

Accumulating0

Unchanged0

Reducing2

Exited0

The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.

Price context

52-week position is market context and does not change the institutional consensus score.

52-week low$3.18 52-week high$7.78

Latest close $10.20 100.0% through the range

Tracked institutions

Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.

Latest observation Mar 31, 2026

Vanguard Group Mar 27, 2026 filed

Invesco May 8, 2026 filed

BlackRock Apr 5, 2024 filed

Detailed institutional research

See what is driving the consensus.

Unlock holder-by-holder changes, ownership history, breadth by period, disclosure timing, and filing-specific signal analysis.

Create free account Compare Investor and Pro

A free account adds watchlists, portfolio tools, and the first live gauge on the default tracker. Investor or Pro reveals research gauges across tracker views and unlocks the detailed research above.

Beneficial ownership filing history

Showing 3 of 5 filing(s) · 2 older require more history access

Holder	Observed / filed	Reported change	Shares	Ownership	Observation	Filing	Latest
Invesco CIK0000914208	Mar 31, 2026 observed May 8, 2026 filed · 38d Schedule 13G amendment	Reported reduction	49.6K -2.0M	12.00% +5.30 pts	$3.91	$5.61	$10.20
Vanguard Group CIK0000102909	Mar 13, 2026 observed Mar 27, 2026 filed · 14d Schedule 13G amendment	Earliest Schedule 13G amendment found	11	12.00%	$3.80	$3.31	$10.20
Invesco CIK0000914208	Sep 30, 2024 observed Nov 8, 2024 filed · 39d Initial Schedule 13G	Initial Schedule 13G	2.0M	6.70%	$7.89	$7.87	$10.20

Explore more institutional activity

Related research

Compare TBI with other securities showing similar institutional activity or recent accumulation across several tracked institutions.

Similar institutional activity

ATROB ASTRONICS CORP-CL B 12/100 Broad reduction RPC RIDGEPOST CAPITAL INC-A 12/100 Broad reduction OXM OXFORD INDUSTRIES INC 12/100 Broad reduction RL RALPH LAUREN CORP 12/100 Broad reduction

Recent multi-institution accumulation

OCGN OCUGEN INC 2 accumulating Aug 7, 2026 DNTH Dianthus Therapeutics, Inc. /DE/ 2 accumulating Aug 7, 2026 SRPT Sarepta Therapeutics, Inc. 2 accumulating Aug 7, 2026 RARE ULTRAGENYX PHARMACEUTICAL IN 2 accumulating Aug 7, 2026